What's Happening?
Incyte has announced promising results from its Phase 1/2 study of VGA039 (latarcibart), an investigational monoclonal antibody therapy for patients with von Willebrand disease (VWD). The study, presented at the ISTH 2026 Congress, demonstrated an 81%
median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types. Latarcibart, which is administered via a once-monthly subcutaneous injection, was found to be safe and well-tolerated. The therapy targets Protein S to enhance hemostasis, potentially offering a significant improvement over current treatments that require frequent intravenous infusions. The ongoing Phase 3 VIVID-6 trial aims to further evaluate latarcibart's efficacy and safety.
Why It's Important?
The development of latarcibart is significant as it addresses a critical need for more effective and convenient prophylactic treatments for VWD, the most common inherited bleeding disorder. Current therapies often involve multiple weekly intravenous infusions, which can be burdensome for patients. Latarcibart's once-monthly dosing could substantially reduce treatment burden while providing consistent bleed protection. This advancement could improve the quality of life for approximately 135,000 people in the U.S. diagnosed with VWD, offering a new standard of care and potentially expanding to other bleeding disorders.
What's Next?
The Phase 3 VIVID-6 trial is currently enrolling participants to further assess the safety and efficacy of latarcibart. If successful, this could lead to regulatory approval and commercialization, providing a new treatment option for VWD patients. Incyte's continued research and development efforts may also explore latarcibart's potential applications in other bleeding disorders, potentially broadening its impact in the field of hematology.
